🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Precision Oncology in Quebec - from laboratory to patient.....precisely! Repare Therapeutics is hosting a Precision Oncology Symposium tomorrow, June 19, from 10 a.m. to 1 p.m. at the adMare BioInnovations Innovation Center in Montreal. admarebio.com/fr/evenements-… #precisiononcology #clinicaltrials

CONFERENCE UPDATE: The abstract is available for Repare Therapeutics's presentation at #ESMOGI from the Phase 1 MINOTAUR trial evaluating lunresertib in combination with FOLFIRI. Learn more here: cslide.ctimeetingtech.com/esmogi24hybrid… #precisiononcology #syntheticlethality #clinicaltrials

Thank you to National Cancer Institute for highlighting Repare Therapeutics's investigation of camonsertib, guided by the FDA Oncology's Project Optimus to optimize dose and schedule. cancer.gov/news-events/ca… #precisiononcology #clinicaltrials

Today at the ESMO - Eur. Oncology Gastrointestinal Cancers Congress 2024, we're presenting positive new data from our MINOTAUR clinical trial combining lunresertib with FOLFIRI. Learn more here: ir.reparerx.com/news-releases/… #precisiononcology #clinicaltrials #syntheticlethality

Today, we announced our second quarter 2024 financial results and provided a business and clinical update. Full press release with additional details: ir.reparerx.com/news-releases/… $RPTX

Tune in with Repare Therapeutics's management team in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference in NYC today. We look forward to connecting in person! Click here to watch the webcast: lnkd.in/eYYbV943 $RPTX #precisiononcology #syntheticlethality

Join Repare Therapeutics at the H.C. Wainwright & Co. 26th Annual Global Investment Conference this week for a company presentation. Click here to join the webcast: ir.reparerx.com/news-releases/… $RPTX

Join us Saturday September at ESMO - European Society for Medical Oncology where we will share new data from Module 1 of our ongoing Phase 1/2 TRESR clinical trial. Learn more here: tinyurl.com/yft5ycph #precisiononcology #syntheticlethality #clinicaltrials

We presented new data at AACR's 15th Annual Ovarian Cancer Research Symposium in Seattle highlighting the impact and inherent chemotherapy resistance of alterations in CCNE1, FBXW7, and PPP2R1A in patients with metastatic ovarian and endometrial cancers. ir.reparerx.com/news-releases/…

Thank you to investigators at Memorial Sloan Kettering Cancer Center for presenting results of our collaboration at ASTRO's annual meeting highlighting encouraging responses for camonsertib with #radiotherapy: lnkd.in/ePapuJWZ

Join Repare's Director of Bioinformatics, Ian Silverman, at the 36th EORTC - National Cancer Institute - AACR Symposium on Molecular Targets and Cancer Therapeutics next week when he will speak about the importance of #bioinformatics to patient trial matching. #precisiononcology

Inviting all attendees of the 36th EORTC-NCI-AACR Symposium at the CCIB in Barcelona to join Dr. Martin Højgaard and Repare Therapeutics for a presentation on the impact of individualised schedule optimisation in our Phase 1 MYTHIC Study. See you at #ENA2024!

Today, we announced our third quarter 2024 financial results and provided a business and clinical update. Full press release with additional details: ir.reparerx.com/news-releases/… $RPTX

Exciting update! Today we announced positive results of the lunresertib and camonsertib combination from the MYTHIC Phase 1 gynecologic expansion clinical trial. Join our webcast at 4:30 pm ET. Learn more here: lnkd.in/eeB3Yp8m

We are delighted to share the latest publication on our PLK4 program, we are proud of our researchers and hopeful that this drug will provide benefit for pediatric patients. lnkd.in/e3PVxbJk #pediatriccancer #PLK4 #neuroblastoma

We are pleased to share that our research exploring lunresertib+camonsertib in CCNE1 amplified #ovarian and #endometrial orthotopic PDX models has been published in Nature Medicine. Read the study here: bit.ly/420FdTp #precisiononcology